Latest revenue
$1.6M
as of 2026-03-31
Latest net income
$-1.8M
as of 2026-03-31
Net margin
-109.5%
as of 2026-03-31
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $91.4M
- Enterprise value
- $91.4M
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- —
- Dividend yield
- 0.0%
- 52-wk high
- $9.33
- 52-wk low
- $2.20
- Beta
- —
- Shares out
- 12.4M
5-year trend
What this company does
ITEM 1. BUSINESS Overview Neuraxis, Inc. (“we”, “us”, the “Company” or “Neuraxis”) is a first-to-market growth-stage medical technology company focused on neuromodulation therapies for chronic and debilitating conditions in gastrointestinal (GI) digestive system, specifically from disorders of the gut-brain interaction (DGBIs) in pediatrics and adults. With several indications in the market and additional clinical trials of Percutaneous Electrical Nerve Field Stimulation (PENFS) in multiple pediatric and adult conditions underway, we are focused on unmet GI healthcare needs in children and adults. We are dedicated to advancing science with our proprietary IB-Stim® therapy, based on our…
AI summary unavailable — showing raw filing excerpt
Generated from NRXS's filing dated 2026-03-19
Key risks
ITEM 1A. RISK FACTORS Risks Relating to Our Business and Our Product Our business and prospects depend entirely on our current products, IB-Stim and RED. Even though we have received FDA clearance for our products, it will remain subject to ongoing regulatory review. If we are unable to maintain regulatory clearance and commercialize our product or are significantly delayed or limited in our commercialization efforts, our business and prospects will be materially harmed. Almost all of our revenues have been derived from sales and royalties from sales of IB-Stim, and we expect to develop, market, and sell other neuromodulation therapy devices for the treatment of chronic and debilitating…
AI summary unavailable — showing raw filing excerpt
Generated from NRXS's filing dated 2026-03-19
Profitability
Gross margin
84.2%
2.7%Operating margin
-219.4%
17.7%Net margin
-218.5%
28.8%Return on equity
-229.5%
42.4%Return on assets
-121.8%
29.7%Leverage
Debt / equity
0.88×
32.1%Debt / assets
46.9%
17.0%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | $1.6M | +79.5% | $-1.8M | +22.7% | -109.5% |
Q4 2025 2025-12-31 | $968.1K | +27.2% | $-1.7M | -18.0% | -176.5% |
Q3 2025 2025-09-30 | $811.4K | +21.7% | $-2.1M | -20.9% | -261.6% |
Q2 2025 2025-06-30 | $894.1K | +46.2% | $-1.7M | +42.1% | -189.1% |
Q1 2025 2025-03-31 | $895.7K | +38.5% | $-2.3M | -7.5% | -254.4% |
Q4 2024 2024-12-31 | $761.2K | — | $-1.4M | — | -190.2% |
Q3 2024 2024-09-30 | $666.6K | +39.6% | $-1.8M | +64.2% | -263.3% |
Q2 2024 2024-06-30 | $611.5K | -5.3% | $-2.9M | -30.5% | -477.1% |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Electromedical & Electrotherapeutic Apparatus · SIC 3845
Your notes
Keep private notes on NRXS — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$2.2M
Insider selling
$0
Net activity
+$2.2M
Distinct insiders
5
Open-market trades over the last 365 days.
Recent transactions
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns NRXS
Institutional value
$8.6M
Total shares held
1.2M
Distinct holders
13
-5 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | AIGH Capital Management LLC | 400.0K | $3.0M | +0 (+0.0%) | No change |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 225.9K | $1.7M | — | New |
| 3 | MONEY CONCEPTS CAPITAL CORP | 225.6K | $1.7M | +3.0K (+1.3%) | Added |
| 4 | PARSONS CAPITAL MANAGEMENT INC/RI | 116.7K | $863.8K | +0 (+0.0%) | No change |
| 5 | VANGUARD FIDUCIARY TRUST CO | 51.9K | $384.0K | — | New |
| 6 | UBS Group AG | 45.3K | $335.5K | -3.5K (-7.1%) | Trimmed |
| 7 | T3 Companies, LLC | 29.9K | $221.4K | — | New |
| 8 | BlackRock, Inc. | 27.4K | $202.4K | — | New |
| 9 | Wealthcare Advisory Partners LLC | 15.2K | $112.4K | +0 (+0.0%) | No change |
| 10 | Mount Yale Investment Advisors, LLC | 11.0K | $81.4K | — | New |
| 11 | LPL Financial LLC | 10.0K | $74.0K | +0 (+0.0%) | No change |
| 12 | Golden State Equity Partners | 780 | $5.8K | — | New |
| 13 | Ulland Investment Advisors, LLC | 1.0K | $7 | +0 (+0.0%) | No change |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once NRXS's latest filing finishes processing.